SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Cardiovascular Diabetology
Honghong ZouGaosi Xu

Abstract

Diabetic kidney disease (DKD) is the most common cause of end stage renal disease. The comprehensive management of DKD depends on combined target-therapies for hyperglycemia, hypertension, albuminuria, and hyperlipaemia, etc. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, the most recently developed oral hypoglycemic agents acted on renal proximal tubules, suppress glucose reabsorption and increase urinary glucose excretion. Besides improvements in glycemic control, they presented excellent performances in direct renoprotective effects and the cardiovascular (CV) safety by decreasing albuminuria and the independent CV risk factors such as body weight and blood pressure, etc. Simultaneous use of SGLT-2 inhibitors and renin-angiotensin-aldosterone system (RAAS) blockers are novel strategies to slow the progression of DKD via reducing inflammatory and fibrotic markers induced by hyperglycaemia more than either drug alone. The available population and animal based studies have described SGLT2 inhibitors plus RAAS blockers. The present review was to systematically review the potential renal benefits of SGLT2 inhibitors combined with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, mineralocorticoid ...Continue Reading

References

Apr 1, 1987·Diabetes/metabolism Reviews·R A DeFronzo, E Ferrannini
Jan 23, 2003·Journal of the American Society of Nephrology : JASN·Volker VallonScott Thomson
Sep 25, 2003·American Journal of Physiology. Renal Physiology·Rocío BautistaBruno Escalante
Apr 28, 2004·Trends in Endocrinology and Metabolism : TEM·Louise M BurrellMark E Cooper
Sep 6, 2006·Hypertension·Sara GiuntiMark E Cooper
Jun 16, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·J E Gerich
Jan 8, 2011·Trends in Pharmacological Sciences·Clifford J Bailey
Jan 14, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Volker Vallon
May 25, 2011·Endocrine Reviews·Muhammad A Abdul-GhaniRalph A Defronzo
Oct 1, 2011·Diabetes, Obesity & Metabolism·R A DeFronzoS Del Prato
Oct 21, 2011·The Journal of Clinical Endocrinology and Metabolism·Ajay ChaudhuriParesh Dandona
Mar 8, 2013·Diabetes, Obesity & Metabolism·J-F YaleG Meininger
Mar 16, 2013·The Journal of Pharmacology and Experimental Therapeutics·Naoki KojimaRichard J Roman
Jan 28, 2014·The Journal of Clinical Investigation·Aurora MerovciRalph A DeFronzo
Mar 29, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Luca De NicolaRoberto Minutolo
Aug 16, 2014·Therapeutic Advances in Endocrinology and Metabolism·Merlin C Thomas
Sep 24, 2014·Drug Design, Development and Therapy·Michael A Nauck
Nov 6, 2014·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Lars HansenBoaz Hirshberg
Jan 30, 2015·Expert Opinion on Drug Safety·André J Scheen
Apr 22, 2015·Current Hypertension Reports·J A Lovshin, R E Gilbert
Jun 13, 2015·European Heart Journal·Ele Ferrannini, Ralph A DeFronzo
Jul 15, 2015·Physiological Reports·Naoki KojimaRichard J Roman
Jul 17, 2015·Diabetes Care·Giulia FerranniniEle Ferrannini
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jan 14, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Yshai YavinEva Johnsson
Jan 29, 2016·European Heart Journal·David FitchettUNKNOWN EMPA-REG OUTCOME® trial investigators
Feb 21, 2016·Cardiovascular Diabetology·Christian SonessonIngrid Gause-Nilsson

❮ Previous
Next ❯

Citations

Aug 23, 2017·Expert Review of Clinical Pharmacology·Konstantinos P ImprialosVasilios G Athyros
Jul 25, 2018·Diabetes, Obesity & Metabolism·Ghadeer K DawwasHaesuk Park
Nov 22, 2018·Expert Opinion on Pharmacotherapy·Pierre Delanaye, André J Scheen
Jan 23, 2020·Journal of Clinical Medicine·Carolina LavozMarta Ruiz-Ortega
Apr 9, 2020·Diabetes, Obesity & Metabolism·Jonatan Barrera-Chimal, Frédéric Jaisser
Apr 29, 2020·International Journal of Molecular Sciences·Anton I KorbutVadim V Klimontov
Jun 6, 2020·Cells·Swayam Prakash Srivastava, Julie E Goodwin
Jan 16, 2018·Expert Opinion on Drug Safety·Agostino ConsoliFabrizio Febo
May 15, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Davida Kruger, Virginia Valentine
Jun 27, 2019·American Journal of Physiology. Renal Physiology·Blythe D Shepard
Sep 13, 2019·Expert Opinion on Drug Metabolism & Toxicology·Maria Del Mar GutierrezPere Domingo
Feb 2, 2021·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Heng-Cheng LuLi-Yu He
Mar 23, 2021·Cardiac Failure Review·Chris Wai Hang LoBernard Man Yung Cheung
May 18, 2021·BioMed Research International·LinLin ChenHu Wang
Jun 8, 2021·Frontiers in Endocrinology·Qing FangDongsheng Ouyang
Jul 31, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Junmin WangGuang Ji
Apr 11, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ali F Abdel-WahabSaeed S Al Ghamdi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Luigi Gnudi, Janaka Karalliedde
Journal of the American Society of Nephrology : JASN
Joshua J NeumillerKatherine R Tuttle
Diabetes Care
Paola FiorettoRoberto Vettor
© 2022 Meta ULC. All rights reserved